Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP).

Conclusion: In summary, IVIg-SN 10% formulation was found to be safe and effective in adult ITP patients (Trial registry at ClinicalTrials.gov, NCT02063789).
PMID: 29736158 [PubMed - in process]

Source: J Korean Med Sci - May 7, 2018 Category: General Medicine Authors: Hong J, Bang SM, Mun YC, Yhim HY, Lee J, Lim HS, Oh D, Korean GC IVIg Investigators Tags: J Korean Med Sci Source Type: research